Vis børsmeldingen
efficacy in AML and MDS patients
BERGEN, Norway, December 11, 2023, - BerGenBio ASA (OSE: BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical needs, today announced that a poster
highlighting final results from a Phase 2 clinical study of its highly selective
AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or
Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of
Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA.
The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical
Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated
in AML and MDS patients. Durable responses were observed across all cohorts with
bemcentinib as monotherapy and in combination with chemotherapy. In addition,
longitudinal samples analyzed from patients enrolled in the study showed that
bemcentinib inhibited pAXL and downstream markers of activation.
Martin Olin, Chief Executive Officer of BerGenBio commented “This large Phase 2
study included 122 patients in several cohorts of AML and MDS patients treated
with bemcentinib monotherapy or in combination with two different
chemotherapies. We are particularly encouraged by the monotherapy activity of
bemcentinib in this study which adds to the mounting evidence of the role of
bemcentinib in restoring the function of patients’ immune response to cancer.”
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Jan Lilleby
jl@lillebyfrisch.no
About Bemcentinib
Bemcentinib is a potentially first-in-class, potent and highly selective
inhibitor of the tyrosine kinase AXL. Extensive studies confirm the ability to
combine bemcentinib with immune checkpoint inhibitors, chemotherapies and
targeted therapies with the goal of improving a patient’s immune response and
delaying the development of chemoresistance. Bemcentinib is currently being
investigated in combination with immune checkpoint inhibition and chemotherapy
in first line NSCLC patients harboring mutations in the STK11 gene, a known
prognostic factor of poor response to existing therapies.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Kilde
